High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 30, Issue 4, 2002, Pages 235-242

  Nakamura, R ^a   Cortez, K ^b   Solomon, S ^a   Battiwalla, M ^a   Gill, V J ^c   Hensel, N ^a   Childs, R ^a   Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytomegalovirus; High dose acyclovir; Non myeloablative stem cell transplantation; pp65 antigenemia; T cell depleted stem cell transplantation

Indexed keywords

ACICLOVIR; BUSULFAN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; VIRUS ANTIGEN; ANTIVIRUS AGENT; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; MATRIX PROTEIN; PHOSPHOPROTEIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA; LIVING DONOR; LYMPHOCYTE DEPLETION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RECIPIENT; SEROLOGY; SIBLING; T LYMPHOCYTE; VIRUS REACTIVATION; ADOLESCENT; AGED; ALLOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DRUG COMBINATION; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK FACTOR; SURVIVAL; VIRUS ACTIVATION;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOSPHOPROTEINS; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL MATRIX PROTEINS; VIRUS ACTIVATION;

EID: 0036675459     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703648     Document Type: Article

References (40)

1. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
2. Risk factors after human bone marrow transplantation
3. Cytomegalovirus pneumonia after bone marrow transplantation: Risk factors and response to therapy
4. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous immunoglobulin in patients with bone marrow transplant
5. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants
6. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
7. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
8. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipient. Results of a placebo-controlled, double blind trial
9. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir at engraftment: A randomized double-blind study
10. Ganciclovir prophylaxis to prevent cytomegalovirus infection after allogeneic marrow transplant
11. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
12. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient
13. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
14. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients
15. European survey of herpes virus resistance to antiviral drugs in bone marrow transplant recipients
16. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes
17. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique
18. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
19. Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients
20. The in vitro activity of acyclovir and related compounds against cytomegalovirus infections
21. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
22. Impact of long-term cyclovir on cytomegalovirus infection and survival after allogenic bone marrow transplantation
23. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection
24. Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia
25. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies
26. + cells predicts outcome in patients with haematological malignancies undergoing T-cell depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
27. Bone marrow transplantation
28. + cell dose predicts relapse and survival after T cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies
29. + cell content but is associated with delayed pancytopenia
30. T cell-depleted bone marrow transplantation and delayed add-back to control acute GVHD and conserve a graft-versus-leukemia effect
31. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
32. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem cell transplantation
33. Definition of cytomegalovirus infection and disease
34. Nonparametric estimation from incomplete observations
35. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
36. CMV reactivation in nonmyeloablative HSCT
37. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation
38. High incidence of early and late CMV infection and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using CAMPATH (anti-CD52 antibody)
39. Incidence of herpes virus infections following nonmyeloablative allogeneic stem cell transplantation
40. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation